Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma.

Chiara BrignoleEnzo CalarcoVeronica BensaElena GiustoPatrizia PerriEleonora CiampiMaria Valeria CorriasSimonetta AstigianoMichele CilliDerik LooEzio BonviniFabio Pastorino Mirco Ponzoni

Published in: Journal for immunotherapy of cancer (2023)

Vobra duo exerts relevant antitumor activity in preclinical B7-H3-expressing NB models and represents a potential candidate for clinical translation.

Keyphrases

cell therapy
randomized controlled trial
clinical trial
mesenchymal stem cells
climate change
study protocol
double blind